口服别孕烷醇酮前药经淋巴转运规避肝代谢提高动物和人生物利用度
别孕烷醇酮因首过肝代谢口服生物利用度差,研究开发了淋巴靶向前药平台Glyph并筛选出GlyphAllo。在189名健康参与者中进行的1/2a期试验显示,该前药可产生治疗相关血浆浓度且耐受良好,并在2a期试验中减少唾液皮质醇应激反应。
要点
- Glyph平台通过连接子化学将药物偶联至膳食脂质,经肠淋巴转运规避肝首过代谢
- GlyphAllo在动物和189名健康人中口服后达治疗相关血浆浓度且总体耐受良好
- 2a期试验中GlyphAllo较安慰剂降低TSST后所有时间点的唾液皮质醇应激反应
核心结论
- 口服GlyphAllo可规避肝首过代谢,在动物和人体产生治疗相关别孕烷醇酮血浆浓度,并初步显示抗焦虑应激反应作用。
研究设计与样本
- 前药设计、合成与体外肠淋巴转运及血浆释放筛选,并在小动物和大动物模型中口服测试。
- 1/2a期临床试验NCT05129865纳入189名健康参与者,进行单次和多次递增口服给药。
- 随后开展随机、双盲、安慰剂对照2a期试验,使用Trier社会应激测试(TSST)评估焦虑。
主要发现
- 多种前药在小动物和大动物口服后达到治疗相关别孕烷醇酮血浆浓度,与体外筛选结果一致。
- 健康参与者单次和多次递增口服GlyphAllo可产生治疗相关血浆浓度,且总体耐受良好。
- GlyphAllo将别孕烷醇酮递送至体循环,并通过GABAA受体正向变构调节产生暴露依赖性药效学效应。
- 2a期试验中GlyphAllo较安慰剂降低TSST后所有时间点的唾液皮质醇应激反应。
临床怎么用
- GlyphAllo作为口服前药策略,有望解决神经精神药物首过代谢限制,支持进一步研究用于情绪和焦虑障碍。
局限性
- 原文未明确报告2a期试验的具体样本量、效应量及安全性详细数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allopregnanolone, an endogenous neuroactive steroid, has antidepressant and anxiolytic activity but poor oral bioavailability because of substantial first-pass hepatic metabolism. To address the broader challenge of oral bioavailability across clinically validated therapeutics in neuropsychiatry, we developed a lymphatic-targeting prodrug technology platform called Glyph in which a drug of interest is conjugated to a dietary lipid molecule using specifically designed linker chemistry to shift drug absorption to the gut lymphatic system, thus bypassing hepatic metabolism. A series of allopregnanolone prodrugs with different functional linker elements was designed, synthesized, and screened in vitro for gut lymphatic transport and plasma release. Multiple prodrugs achieved therapeutically relevant plasma allopregnanolone concentrations after oral dosing in small- and large-animal models consistent with results from in vitro screening. A triglyceride-mimetic prodrug, GlyphAllo (SPT-300 or Glyph Allopregnanolone), was selected and tested in a phase 1/2a clinical trial (NCT05129865) in 189 healthy participants. Single- and multiple-ascending oral dosing showed that this prodrug could generate therapeutically relevant plasma concentrations in trial participants. GlyphAllo was generally well tolerated and resulted in delivery of allopregnanolone to the systemic circulation and exposure-dependent pharmacodynamic effects via GABAA (γ-aminobutyric acid type A) receptor positive allosteric modulation. In a subsequent randomized, double-blind, placebo-controlled phase 2a trial using the Trier Social Stress Test (TSST), a validated clinical test for anxiety, GlyphAllo was reported to reduce the salivary cortisol stress response compared with placebo at all post-TSST time points. Collectively, these data support further investigation of GlyphAllo for treating mood and anxiety disorders.
引用
- Simpson JS, Quach T, Han S, et al. An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans. Sci Transl Med. 2026. PMID: 41880520. doi:10.1126/scitranslmed.adu2352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。